Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03946358 |
Recruitment Status :
Recruiting
First Posted : May 10, 2019
Last Update Posted : November 18, 2022
|
Sponsor:
Centre Hospitalier Universitaire de Besancon
Collaborators:
Roche Pharma AG
National Cancer Institute, France
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Besancon
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | September 2024 |
Estimated Study Completion Date : | October 2025 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):